
Ipca Labs Sells Mahad Unit for ₹16.90 Cr
Ipca Laboratories Ltd. is closing its Mahad, Maharashtra drug intermediates manufacturing unit and selling the leasehold land and old factory buildings for ₹16.90 crores to M/s. ICMC Corporation Ltd. This move is part of the company's strategy to optimize operations, reduce manufacturing units, and minimize costs. The written down value of the assets is ₹13.21 crores. The drug intermediates produced at the Mahad unit have been shifted to other facilities, and the plant and machinery will also be transferred. Ipca Laboratories stated that this closure and sale will not impact the company's overall business or financials. The transaction is expected to be completed by March 31, 2027, subject to necessary approvals. M/s. ICMC Corporation Ltd. is not a related party to Ipca Laboratories.
Key Highlights
- Ipca Labs to sell Mahad drug intermediates unit for ₹16.90 Cr.
- Closure part of operational strategy to reduce units and costs.
- No expected impact on company's business and financials.
- Sale includes leasehold land and old factory buildings.
- Transaction completion targeted by March 31, 2027.
Price Impact
More from IPCALAB